Global Age-related Macular Degeneration Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • Age-related Macular Degeneration market report explains the definition, types, applications, major countries, and major players of the Age-related Macular Degeneration market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Bayer HealthCare

    • F Hoffmann-La Roche

    • Novartis

    • Regeneron Pharmaceuticals

    • Alcon

    • Allergan

    • Avalanche

    • Bausch+Lomb

    • Gilead Sciences

    • Iconic Therapeutics

    • Neurotech Pharmaceuticals

    • Ohr Pharmaceutical

    By Type:

    • Wet AMD

    • Dry AMD

    By End-User:

    • Drugstore

    • Hospital

    • Others

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Age-related Macular Degeneration Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Age-related Macular Degeneration Outlook to 2028- Original Forecasts

    • 2.2 Age-related Macular Degeneration Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Age-related Macular Degeneration Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Age-related Macular Degeneration Market- Recent Developments

    • 6.1 Age-related Macular Degeneration Market News and Developments

    • 6.2 Age-related Macular Degeneration Market Deals Landscape

    7 Age-related Macular Degeneration Raw Materials and Cost Structure Analysis

    • 7.1 Age-related Macular Degeneration Key Raw Materials

    • 7.2 Age-related Macular Degeneration Price Trend of Key Raw Materials

    • 7.3 Age-related Macular Degeneration Key Suppliers of Raw Materials

    • 7.4 Age-related Macular Degeneration Market Concentration Rate of Raw Materials

    • 7.5 Age-related Macular Degeneration Cost Structure Analysis

      • 7.5.1 Age-related Macular Degeneration Raw Materials Analysis

      • 7.5.2 Age-related Macular Degeneration Labor Cost Analysis

      • 7.5.3 Age-related Macular Degeneration Manufacturing Expenses Analysis

    8 Global Age-related Macular Degeneration Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Age-related Macular Degeneration Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Age-related Macular Degeneration Export by Region (Top 10 Countries) (2017-2028)

    9 Global Age-related Macular Degeneration Market Outlook by Types and Applications to 2022

    • 9.1 Global Age-related Macular Degeneration Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Wet AMD Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Dry AMD Consumption and Growth Rate (2017-2022)

    • 9.2 Global Age-related Macular Degeneration Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Drugstore Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Others Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Age-related Macular Degeneration Market Analysis and Outlook till 2022

    • 10.1 Global Age-related Macular Degeneration Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Age-related Macular Degeneration Consumption (2017-2022)

      • 10.2.2 Canada Age-related Macular Degeneration Consumption (2017-2022)

      • 10.2.3 Mexico Age-related Macular Degeneration Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.2 UK Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.3 Spain Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.4 Belgium Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.5 France Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.6 Italy Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.7 Denmark Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.8 Finland Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.9 Norway Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.10 Sweden Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.11 Poland Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.12 Russia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.3.13 Turkey Age-related Macular Degeneration Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.2 Japan Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.3 India Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.4 South Korea Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.5 Pakistan Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.6 Bangladesh Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.7 Indonesia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.8 Thailand Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.9 Singapore Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.10 Malaysia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.11 Philippines Age-related Macular Degeneration Consumption (2017-2022)

      • 10.4.12 Vietnam Age-related Macular Degeneration Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.2 Colombia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.3 Chile Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.4 Argentina Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.5 Venezuela Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.6 Peru Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.7 Puerto Rico Age-related Macular Degeneration Consumption (2017-2022)

      • 10.5.8 Ecuador Age-related Macular Degeneration Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Age-related Macular Degeneration Consumption (2017-2022)

      • 10.6.2 Kuwait Age-related Macular Degeneration Consumption (2017-2022)

      • 10.6.3 Oman Age-related Macular Degeneration Consumption (2017-2022)

      • 10.6.4 Qatar Age-related Macular Degeneration Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Age-related Macular Degeneration Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Age-related Macular Degeneration Consumption (2017-2022)

      • 10.7.2 South Africa Age-related Macular Degeneration Consumption (2017-2022)

      • 10.7.3 Egypt Age-related Macular Degeneration Consumption (2017-2022)

      • 10.7.4 Algeria Age-related Macular Degeneration Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Age-related Macular Degeneration Consumption (2017-2022)

      • 10.8.2 New Zealand Age-related Macular Degeneration Consumption (2017-2022)

    11 Global Age-related Macular Degeneration Competitive Analysis

    • 11.1 Bayer HealthCare

      • 11.1.1 Bayer HealthCare Company Details

      • 11.1.2 Bayer HealthCare Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Bayer HealthCare Age-related Macular Degeneration Main Business and Markets Served

      • 11.1.4 Bayer HealthCare Age-related Macular Degeneration Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 F Hoffmann-La Roche

      • 11.2.1 F Hoffmann-La Roche Company Details

      • 11.2.2 F Hoffmann-La Roche Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 F Hoffmann-La Roche Age-related Macular Degeneration Main Business and Markets Served

      • 11.2.4 F Hoffmann-La Roche Age-related Macular Degeneration Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Novartis

      • 11.3.1 Novartis Company Details

      • 11.3.2 Novartis Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Novartis Age-related Macular Degeneration Main Business and Markets Served

      • 11.3.4 Novartis Age-related Macular Degeneration Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Regeneron Pharmaceuticals

      • 11.4.1 Regeneron Pharmaceuticals Company Details

      • 11.4.2 Regeneron Pharmaceuticals Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Regeneron Pharmaceuticals Age-related Macular Degeneration Main Business and Markets Served

      • 11.4.4 Regeneron Pharmaceuticals Age-related Macular Degeneration Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Alcon

      • 11.5.1 Alcon Company Details

      • 11.5.2 Alcon Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Alcon Age-related Macular Degeneration Main Business and Markets Served

      • 11.5.4 Alcon Age-related Macular Degeneration Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Allergan

      • 11.6.1 Allergan Company Details

      • 11.6.2 Allergan Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Allergan Age-related Macular Degeneration Main Business and Markets Served

      • 11.6.4 Allergan Age-related Macular Degeneration Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Avalanche

      • 11.7.1 Avalanche Company Details

      • 11.7.2 Avalanche Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Avalanche Age-related Macular Degeneration Main Business and Markets Served

      • 11.7.4 Avalanche Age-related Macular Degeneration Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Bausch+Lomb

      • 11.8.1 Bausch+Lomb Company Details

      • 11.8.2 Bausch+Lomb Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Bausch+Lomb Age-related Macular Degeneration Main Business and Markets Served

      • 11.8.4 Bausch+Lomb Age-related Macular Degeneration Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    • 11.9 Gilead Sciences

      • 11.9.1 Gilead Sciences Company Details

      • 11.9.2 Gilead Sciences Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.9.3 Gilead Sciences Age-related Macular Degeneration Main Business and Markets Served

      • 11.9.4 Gilead Sciences Age-related Macular Degeneration Product Portfolio

      • 11.9.5 Recent Research and Development Strategies

    • 11.10 Iconic Therapeutics

      • 11.10.1 Iconic Therapeutics Company Details

      • 11.10.2 Iconic Therapeutics Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.10.3 Iconic Therapeutics Age-related Macular Degeneration Main Business and Markets Served

      • 11.10.4 Iconic Therapeutics Age-related Macular Degeneration Product Portfolio

      • 11.10.5 Recent Research and Development Strategies

    • 11.11 Neurotech Pharmaceuticals

      • 11.11.1 Neurotech Pharmaceuticals Company Details

      • 11.11.2 Neurotech Pharmaceuticals Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.11.3 Neurotech Pharmaceuticals Age-related Macular Degeneration Main Business and Markets Served

      • 11.11.4 Neurotech Pharmaceuticals Age-related Macular Degeneration Product Portfolio

      • 11.11.5 Recent Research and Development Strategies

    • 11.12 Ohr Pharmaceutical

      • 11.12.1 Ohr Pharmaceutical Company Details

      • 11.12.2 Ohr Pharmaceutical Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

      • 11.12.3 Ohr Pharmaceutical Age-related Macular Degeneration Main Business and Markets Served

      • 11.12.4 Ohr Pharmaceutical Age-related Macular Degeneration Product Portfolio

      • 11.12.5 Recent Research and Development Strategies

    12 Global Age-related Macular Degeneration Market Outlook by Types and Applications to 2028

    • 12.1 Global Age-related Macular Degeneration Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Wet AMD Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Dry AMD Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Age-related Macular Degeneration Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Drugstore Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Others Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Age-related Macular Degeneration Market Analysis and Outlook to 2028

    • 13.1 Global Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.2.2 Canada Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.2 UK Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.3 Spain Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.5 France Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.6 Italy Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.8 Finland Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.9 Norway Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.11 Poland Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.12 Russia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.2 Japan Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.3 India Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.3 Chile Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.6 Peru Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.6.3 Oman Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Age-related Macular Degeneration Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Age-related Macular Degeneration Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Age-related Macular Degeneration Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Age-related Macular Degeneration

    • Figure of Age-related Macular Degeneration Picture

    • Table Global Age-related Macular Degeneration Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Age-related Macular Degeneration Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Wet AMD Consumption and Growth Rate (2017-2022)

    • Figure Global Dry AMD Consumption and Growth Rate (2017-2022)

    • Figure Global Drugstore Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Others Consumption and Growth Rate (2017-2022)

    • Figure Global Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Table North America Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure United States Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Canada Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Mexico Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table Europe Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure Germany Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure UK Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Spain Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Belgium Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure France Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Italy Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Denmark Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Finland Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Norway Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Sweden Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Poland Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Russia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Turkey Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table APAC Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure China Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Japan Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure India Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure South Korea Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Thailand Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Singapore Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Philippines Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table South America Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure Brazil Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Colombia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Chile Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Argentina Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Peru Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table GCC Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure Bahrain Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Oman Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Qatar Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table Africa Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure Nigeria Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure South Africa Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Egypt Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure Algeria Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table Oceania Age-related Macular Degeneration Consumption by Country (2017-2022)

    • Figure Australia Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Age-related Macular Degeneration Consumption and Growth Rate (2017-2022)

    • Table Bayer HealthCare Company Details

    • Table Bayer HealthCare Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bayer HealthCare Age-related Macular Degeneration Main Business and Markets Served

    • Table Bayer HealthCare Age-related Macular Degeneration Product Portfolio

    • Table F Hoffmann-La Roche Company Details

    • Table F Hoffmann-La Roche Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table F Hoffmann-La Roche Age-related Macular Degeneration Main Business and Markets Served

    • Table F Hoffmann-La Roche Age-related Macular Degeneration Product Portfolio

    • Table Novartis Company Details

    • Table Novartis Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Novartis Age-related Macular Degeneration Main Business and Markets Served

    • Table Novartis Age-related Macular Degeneration Product Portfolio

    • Table Regeneron Pharmaceuticals Company Details

    • Table Regeneron Pharmaceuticals Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Regeneron Pharmaceuticals Age-related Macular Degeneration Main Business and Markets Served

    • Table Regeneron Pharmaceuticals Age-related Macular Degeneration Product Portfolio

    • Table Alcon Company Details

    • Table Alcon Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Alcon Age-related Macular Degeneration Main Business and Markets Served

    • Table Alcon Age-related Macular Degeneration Product Portfolio

    • Table Allergan Company Details

    • Table Allergan Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Age-related Macular Degeneration Main Business and Markets Served

    • Table Allergan Age-related Macular Degeneration Product Portfolio

    • Table Avalanche Company Details

    • Table Avalanche Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Avalanche Age-related Macular Degeneration Main Business and Markets Served

    • Table Avalanche Age-related Macular Degeneration Product Portfolio

    • Table Bausch+Lomb Company Details

    • Table Bausch+Lomb Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bausch+Lomb Age-related Macular Degeneration Main Business and Markets Served

    • Table Bausch+Lomb Age-related Macular Degeneration Product Portfolio

    • Table Gilead Sciences Company Details

    • Table Gilead Sciences Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Gilead Sciences Age-related Macular Degeneration Main Business and Markets Served

    • Table Gilead Sciences Age-related Macular Degeneration Product Portfolio

    • Table Iconic Therapeutics Company Details

    • Table Iconic Therapeutics Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Iconic Therapeutics Age-related Macular Degeneration Main Business and Markets Served

    • Table Iconic Therapeutics Age-related Macular Degeneration Product Portfolio

    • Table Neurotech Pharmaceuticals Company Details

    • Table Neurotech Pharmaceuticals Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Neurotech Pharmaceuticals Age-related Macular Degeneration Main Business and Markets Served

    • Table Neurotech Pharmaceuticals Age-related Macular Degeneration Product Portfolio

    • Table Ohr Pharmaceutical Company Details

    • Table Ohr Pharmaceutical Age-related Macular Degeneration Sales, Price, Value and Gross Profit (2017-2022)

    • Table Ohr Pharmaceutical Age-related Macular Degeneration Main Business and Markets Served

    • Table Ohr Pharmaceutical Age-related Macular Degeneration Product Portfolio

    • Figure Global Wet AMD Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Dry AMD Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Drugstore Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Others Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Table North America Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure United States Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure Germany Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure China Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure Brazil Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Age-related Macular Degeneration Consumption Forecast by Country (2022-2028)

    • Figure Australia Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Age-related Macular Degeneration Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.